We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
ALCLS.PA

Price
1.30
Stock movement up
+0.13 (11.28%)
Company name
Cellectis
Exchange
(PA
,
Currency
EUR
)
Sector
Healthcare >
Biotechnology
Market cap
130.32M
Ent value
237.69M
Price/Sales
4.48
Price/Book
1.01
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-1.44%
1 year return
-44.95%
3 year return
-27.86%
5 year return
-40.78%
10 year return
-28.23%
Last updated: 2025-04-12

DIVIDENDS

ALCLS.PA does not pay dividends or no data was received

VALUATION

Valuation Ratios

Valuation Ratios data
Trailing P/E-
Price to OCF2.08
Price to FCF2.16
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Valuation (Sales/Book Value) data
Price to Sales4.48
Price to Book1.01
EV to Sales8.18

FINANCIALS

Per share

Per share data
Current share count100.09M
EPS (TTM)-0.95
FCF per share (TTM)0.67

Income statement

Income statement data
Revenue (TTM)29.07M
Gross profit (TTM)30.35M
Operating income (TTM)-78.85M
Net income (TTM)-85.55M
EPS (TTM)-0.95
EPS (1y forward)-

Margins

Margins data
Gross margin (TTM)104.39%
Operating margin (TTM)-271.23%
Profit margin (TTM)-294.25%

Balance Sheet

Please create a free account or log in to access this chart
Balance Sheet data
Cash159.09M
Net receivables27.88M
Total current assets294.37M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment171.06M
Total assets395.88M
Accounts payable18.51M
Short/Current long term debt91.52M
Total current liabilities165.65M
Total liabilities266.45M
Shareholder's equity129.42M
Net tangible assets0.00

Cash flow

Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)62.75M
Capital expenditures (TTM)2.37M
Free cash flow (TTM)60.38M
Dividends paid (TTM)0.00

Financial returns

Please create a free account or log in to access this chart
Financial returns data
Return on Equity-66.10%
Return on Assets-21.61%
Return on Invested Capital-46.43%
Cash Return on Invested Capital32.77%

STOCK INFORMATION

Stock chart

Stock price data
Open1.20
Daily high1.38
Daily low1.19
Daily Volume630K
All-time high40.90
1y analyst estimate5.00
Beta3.20
EPS (TTM)-0.95
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Downside potential data
ALCLS.PAS&P500
Current price drop from All-time high-96.82%-12.89%
Highest price drop-97.80%-56.47%
Date of highest drop31 Oct 20239 Mar 2009
Avg drop from high-56.29%-11.07%
Avg time to new high186 days12 days
Max time to new high2531 days1805 days
COMPANY DETAILS
ALCLS.PA (Cellectis) company logo
Marketcap
130.32M
Marketcap category
Small-cap
Description
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Employees
216
Website
https://www.cellectis.com
Investor relations
-
SEC filings
ALCLS.PA SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
UNDERSTAND THE BUSINESS
COMPANY NEWS
All newsPress releases
No items found
Disclaimer
Skyfall Technology OÜ assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
Menu
HomePortfolio ManagementCompany ScreenerGreen InvestmentExchangesContact Us
Language
ENHUNOSVDAFIESDENLFRITPTPLCSSKROELTRRUAF
© 2024 Skyfall Technology OÜ All Rights Reserved